The influence of a new antiarrhythmic drug, Craviten (M-71) on coronary flow.
Craviten (M-71) increases the coronary flow, depresses the rate of contractions, and transiently depresses the contractile force of the cat heart in vitro and in situ. As the action of the drug is short-lasting, its usefulness in treatment of acute cardiac insufficiency accompanied by pain is suggested. It is also potentially useful in cardiac insufficiencies accompanied by arrhythmia.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D003326:Coronary Circulation / Q000187:drug effects*; D004176:Dipyridamole / Q000494:pharmacology; D005029:Ethylenediamines / Q000494:pharmacology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D005996:Nitroglycerin / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D005029:Ethylenediamines; C030706:butobendin; D004176:Dipyridamole; D005996:Nitroglycerin